A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors

Open to people ages 18 years and up

• All Parts: Participants must have disease that is relapsed, refractory, or intolerant to standard of care. Participants must have histologically or cytologically confirmed metastatic malignancy.
• Participants must have one of the following tumor types:
  • Parts A and B: Participants must have metastatic or unresectable cutaneous melanoma.
  • Part C: Participants must have one of the following tumor types:
    • Cutaneous Melanoma
    • Non-small Cell Lung Cancer (NSCLC)
    • Colorectal Cancer (CRC)
    • Pancreatic Cancer
    • Mesothelioma
• A pre-treatment biopsy or submission of archival tissue is required
• For participants with cutaneous melanoma
  • Must have been previously treated with an anti-programmed death-1 (anti-PD-1) or anti-programmed death ligand-1 (anti-PD-L1) agent given alone or with other therapies.
  • Participants with a targetable BRAF mutation must have been treated with, been intolerant of, or been deemed ineligible to receive treatment with BRAF/MEK targeted therapy prior to study entry.
• Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1
• Measurable disease per RECIST v1.1 at baseline

• History of another malignancy within 3 years before the first dose of study drug, or any evidence of residual disease from a previously diagnosed malignancy. Exceptions are malignancies with a negligible risk of metastasis or death.
• Active central nervous system metastases or leptomeningeal disease. Participants with previously treated brain metastases may participate provided they are:
  • clinically stable for at least 4 weeks prior to study entry after brain metastasis treatment,
  • they have no new or enlarging brain metastases,
  • and are off of corticosteroids prescribed for symptoms associated with brain metastases for at least 7 days prior to the first dose of study drug.
• Prior therapies cannot include any drugs targeting CD228 or 4-1BB
• Immunotherapy, biologics, and/or other approved or investigational antitumor treatment that is not completed 4 weeks prior to first dose of study drug, or within 2 weeks prior to the first dose of study drug if the underlying disease has progressed on treatment
• Melanoma subtypes including acral, uveal, and mucosal are excluded